TG and neoplasm: Thus, we speculated that serum CA19-9 levels might serve as a surrogate marker for PTC in place of the serum Tg level in patients for whom follow-up on the basis of Tg levels is not appropriate (such as patients with positive serum TgAb) since there is currently no useful tumor marker for use in patients whose serum is TgAb-positive.